Zhengye Biotechnology Holding ZYBT
NASDAQ ZYBT
$1.88 +0.03 (+1.39%)
At close: Aug 20, 2026 · 12:43 PM UTC

Zhengye Biotechnology Holding (ZYBT) Other Accumulated Expenses (2024 - 2025)

Zhengye Biotechnology Holding (ZYBT) posted quarterly Other Accumulated Expenses of $20325.5 for Q4 2024.

Zhengye Biotechnology Holding (ZYBT) Other Accumulated Expenses (2024 - 2025) Analysis & Trends

Zhengye Biotechnology Holding (ZYBT) has reported Other Accumulated Expenses for 1 consecutive years, with $20325.5 the latest figure, recorded in Q4 2024.

  • In Q4 2024, Other Accumulated Expenses changed N/A year-over-year to $20325.5; the TTM figure through Dec 2024 stood at $20325.5 (changed N/A YoY), while the FY2024 annual figure was $20000.0, changed N/A from the prior year.
  • Other Accumulated Expenses steadied at $20325.5 in Q4 2024 per ZYBT's latest filing.
  • Across five years, Other Accumulated Expenses topped out at $20325.5 in Q4 2024 and bottomed at $20325.5 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 43.96 Bn 43.00 Bn -
2 Teva Pharmaceutical Industries 43.23 Bn 39.58 Bn 2.15 Bn
3 Zoetis 31.76 Bn 30.08 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.68 Bn 22.88 Bn 5.10 Bn
5 United Therapeutics 22.27 Bn 19.61 Bn 683.80 Mn
6 Viatris 18.69 Bn 17.81 Bn 1.46 Bn
7 Neurocrine Biosciences 15.56 Bn 15.17 Bn 935.80 Mn
8 Elanco Animal Health 11.78 Bn 11.25 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.13 Bn 9.97 Bn -
10 Zhengye Biotechnology Holding 88.82 Mn 81.50 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2025 4.56 Mn
Dec 31, 2024 20,325.50